Vision

Cancer thrives by escaping immune surveillance. Inovactis aims at priming the dendritic cells against the patient neo antigens in order to restore a strong immune response specific for the cancer cells. .

Because patients can be segmented according to cancer biomarkers, Inovactis has developed custom made immunotherapies against any neo-antigens, making possible the advent of personalized targeted therapies.

Immunotherapy

Inovactis immunotherapy is a yeast based platform rationally designed by synthetic biology. Through a patented process, our yeast platform can target dendritic cells directly in vivo, without any cell extraction from the patient. More importantly, it can target several patient neoantigens at the same time and induce the immune system against all the specific targets with a minimal toxicity.

Inovactis immunotherapy can target any cancer type through a personalized medicine process flow, opening a broad therapeutic landscape. At present, Inovactis platform is designed to target melanoma with patient tailored immunotherapy targeting its own neoantigens. Melanoma is an aggressive skin cancer affecting 400,000 people in Europe in 2017 with a market estimated at 5 billion euros in 2023. In addition, Inovactis has also engineered a platform to target 3 shared neoantigens from the colon adenocarcinoma MSS, which represents 85% of all the colon cancers.

The Team


Co-Founders

Clément de Obaldia , Inovactis president, is both an aeronautics engineer and a synthetic biology engineer. He is experienced in team working as air traffic controller at Paris Orly airport. In 2015, he led the Genopole research team that competed for the iGEM competition (MIT).


Pierre-Yves Nogue , Inovactis co-founder, is a synthetic biology engineer. Previously, he was awarded an entrepreneur prize for his lab work cloning automation project. He also created the Genopole team for the iGEM competition in 2015.



Scientific board

Pr Bruno Colombo is scientific advisor and future board member. With more than 29 international peer reviewed articles, Pr Bruno Colombo has specialized in immunotherapies using dendritic cells.



Strategic board

Dr Jean-Jacques Garaud is strategic advisor, physician, and future board member. He was head of Novartis early clinical development (2001-2005) and world director of Roche early development in 2012. In 2016, he was appointed CEO of Inotrem. His deep knowledge of the pharmaceutical industry and the clinical process is very valuable to Inovactis.

Carole Pottier-Garaud is Inovactis pre-clinical project development chief. She has more than 20 years of experience in clinical research. She was head of the service « Promotion and clinical parternships » at Gustave Roussy (2005-2012), the european cancer institute of reference.

Contact


For any questions, please contact us :

De Obaldia Clément
Mail : clementdeobaldia@inovactis.com
Tel : 0661997802

Nogue Pierre-Yves
Mail : pierreyves.nogue@inovactis.com

Elements

Text

This is bold and this is strong. This is italic and this is emphasized. This is superscript text and this is subscript text. This is underlined and this is code: for (;;) { ... }. Finally, this is a link.


Heading Level 2

Heading Level 3

Heading Level 4

Heading Level 5
Heading Level 6

Blockquote

Fringilla nisl. Donec accumsan interdum nisi, quis tincidunt felis sagittis eget tempus euismod. Vestibulum ante ipsum primis in faucibus vestibulum. Blandit adipiscing eu felis iaculis volutpat ac adipiscing accumsan faucibus. Vestibulum ante ipsum primis in faucibus lorem ipsum dolor sit amet nullam adipiscing eu felis.

Preformatted

i = 0;

while (!deck.isInOrder()) {
    print 'Iteration ' + i;
    deck.shuffle();
    i++;
}

print 'It took ' + i + ' iterations to sort the deck.';

Lists

Unordered

  • Dolor pulvinar etiam.
  • Sagittis adipiscing.
  • Felis enim feugiat.

Alternate

  • Dolor pulvinar etiam.
  • Sagittis adipiscing.
  • Felis enim feugiat.

Ordered

  1. Dolor pulvinar etiam.
  2. Etiam vel felis viverra.
  3. Felis enim feugiat.
  4. Dolor pulvinar etiam.
  5. Etiam vel felis lorem.
  6. Felis enim et feugiat.

Icons

Actions

Table

Default

Name Description Price
Item One Ante turpis integer aliquet porttitor. 29.99
Item Two Vis ac commodo adipiscing arcu aliquet. 19.99
Item Three Morbi faucibus arcu accumsan lorem. 29.99
Item Four Vitae integer tempus condimentum. 19.99
Item Five Ante turpis integer aliquet porttitor. 29.99
100.00

Alternate

Name Description Price
Item One Ante turpis integer aliquet porttitor. 29.99
Item Two Vis ac commodo adipiscing arcu aliquet. 19.99
Item Three Morbi faucibus arcu accumsan lorem. 29.99
Item Four Vitae integer tempus condimentum. 19.99
Item Five Ante turpis integer aliquet porttitor. 29.99
100.00

Buttons

  • Disabled
  • Disabled

Form